CanSino Biologics, Inc. Class H (HK:6185) has released an update.
CanSino Biologics Inc. has announced a new grant agreement with the Bill & Melinda Gates Foundation for over $17 million to support the development of its non-infectious polio vaccine candidate, CS-2036, along with its use in combined vaccine candidates. The grant will facilitate the candidate’s clinical research, process development, and scale-up, with the aim to offer an affordable polio vaccine for developing countries post-eradication. Investors are cautioned due to the inherent uncertainties in clinical trials and regulatory approvals.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
